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Alexandre A. Boudreault,1,2 Hu Xie,1 Wendy Leisenring,1 Janet Englund,3
Lawrence Corey,1 Michael Boeckh1The impact of cytokines induced during influenza infection has been described, but the effect of corticosteroids
on clinical outcomes is unclear. Although antiviral therapy has been well studied in immunocompetent subjects,
few data exist on its clinical efficacy in immunocompromised populations. Data from 143 hematopoietic cell
transplant recipients with documented seasonal influenza infectionwere reviewed to examine the impact of dif-
ferent corticosteroid regimens and antiviral therapyon clinical outcomes. Inmultivariable analyses, therewas no
observed difference between patients who received no, low doses (\1 mg/kg/day), or high doses ($1 mg/kg/
day) of corticosteroids with regard to the development of lower respiratory tract disease (LRD), hypoxemia,
need for mechanical ventilation, or death. However, treatment with high-dose steroids was associated with
a trend toward prolonged viral shedding (odds ratio [OR], 3.3; 95% confidence interval [CI], 1.0-11; P5 .05).
Inmultivariable analyses, antiviral therapy initiated to treat upper respiratory tract infection (URI)was associated
with fewer cases of LRD (OR, 0.04; 95% CI, 0-0.2; P\.01) and fewer hypoxemia episodes (OR, 0.3; 95% CI,
0.1-0.9; P 5 .03). Our results suggest that corticosteroids are not associated with adverse clinical outcomes
in hematopoietic cell transplant recipients infected with influenza, although use of higher doses may delay viral
clearance. Antiviral therapy initiated during the URI phase reduced the risk of LRD and hypoxemia.
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Influenza virus infection in hematopoietic cell trans-
plant (HCT) recipients has a highpotential to progress to
lower respiratory tract disease (LRD), which is associated
with high rates of morbidity andmortality [1-6]. Because
inflammatory cytokine response induced during severe
influenza infections may potentially be harmful in the
human host [7,8], some investigators have suggested
that corticosteroids could be used as an adjunct therapy
for influenza in specific patients [9,10]. However,
analysis of the effect of steroids in large clinical cohorts
or randomized trials is lacking. In an animal model of
influenza, intranasal lavage with corticosteroids has1Fred Hutchinson Cancer Research Center, Seattle,
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6/j.bbmt.2010.09.014been shown to decrease pulmonary histopathologic
changes [11]. In a previous study at our center, HCT pa-
tientswith influenzaLRDwere less likely tohave received
corticosteroids at initial diagnosis [4], but the sample size
was insufficient to control for possible confounders. Im-
portantly, prolongation of viral shedding is a potential
drawback of corticosteroid therapy during influenza
infection [4,12]. Also, steroids are generally not
recommended in immunocompromised patients with
viral infection based on the increased risk of LRD
associated with their use in paramyxovirus infections
[13,14].
Antiviral therapy is recommended for the treatment
of influenza infection based on data from clinical trials
performed in immunocompetent populations [15-17].
There are very few studies documenting the efficacy
and the impact of timing of antiviral drug treatment
in immunocompromised patients [2,4,18-20]. One
retrospective study conducted in patients with
hematologic malignancies suggested that patients who
progressed to influenza LRD were less likely to have
received antiviral agents during the upper respiratory
phase of their infection [2].
To define the impact of corticosteroid and antiviral
treatment on important clinical outcomes, we conducted979
980 Biol Blood Marrow Transplant 17:979-986, 2011A. A. Boudreault et al.a retrospective, single-center study on HCT patients in-
fected with seasonal influenza. Specifically, we analyzed
the effect of antiviral drugs given to treat upper respira-
tory tract infection (URI) alongwith the impact of differ-
ent corticosteroid dosing regimens given mainly for the
treatment of graft-versus-host disease (GVHD) at the
time when influenza infection was first documented.METHODS
Population
We reviewed records from the Fred Hutchinson
Cancer Research Center (FHCRC) to identify all
HCTpatients with a respiratory tract specimen positive
for seasonal influenza from 7 days prior to transplanta-
tion through any time after transplantation from
September 1989 through July 2009. Only the first epi-
sode of influenza infection was analyzed. Clinical data
were obtained from research databases and supple-
mented by review of medical records. All participants
provided written informed consent and the study was
approved by the FHCRC institutional review board.
Virologic Procedures and Clinical Management
A standardized protocol for respiratory virus detec-
tion is used for all patients undergoing HCT at
FHCRC. Throughout the study period, a nasopharyn-
geal-throat (NPT)washwas recommended for patients
presenting withURI symptoms, and a bronchoalveolar
lavage (BAL) was performed in patients with new pul-
monary infiltrates, whenever feasible. NPT washes
were classified as upper respiratory tract specimens,
and tracheal aspirates, BAL and lung biopsies were
classified as lower respiratory tract specimens. Viral
culture and direct fluorescent antibody staining was
performed on all respiratory specimens; in addition, re-
verse transcriptase polymerase chain amplification has
been performed since March 2006 [21]. NPT washes
were generally obtained weekly until clearance of the
infection. Antiviral therapy was prescribed at the dis-
cretion of treating physician.
Definitions
URI was defined as influenza documented in an up-
per respiratory tract specimen in a patient with
compatible symptoms. LRD was defined as a new pul-
monary infiltrate in association with a positive lower re-
spiratory tract specimen or a positive upper respiratory
tract specimen for patients who did not undergo BAL.
A URI without an LRD diagnosis within the first 72
hours defined a URI presentation. Hypoxemia was de-
fined as ambient air oxygen saturation \90% or the
need for O2 supplementation, and mechanical ventila-
tion was defined as any mechanical ventilation assis-
tance, both occurring during the 28 days following
positive influenza specimen. Death was considered tobe associated with influenza if a patient died of respira-
tory failure and influenza virus was thought to be con-
tributory to the lung injury. Nonneoplasic disease,
chronicmyelogenous leukemia (CML) inchronic phase,
and cancer in remission were categorized as nonad-
vanced disease; CML in accelerated phase or blast crisis,
disease in relapse, and associated with second transplan-
tation were categorized as advanced disease.
Antiviral therapy for URI was defined as treatment
with rimantadine, amantadine, oseltamivir, or zanami-
vir that was prescribed to treat influenza URI. M-2 in-
hibitors were considered only if used to treat influenza
A infection. The timing of initiation of antiviral refers
to the delay between the first positive influenza test and
the first day of treatment. Time from onset of symp-
toms to treatment was not assessed because it could
not be reliably done because of the retrospective
nature of the study.
For the categorization of lymphocytopenia we used
the lowest absolute lymphocyte count encountered
during the 2 weeks prior to influenza diagnosis. For the
analysis of corticosteroid therapy, patients were
classified based on the dosing at the time of influenza
diagnosis: no corticosteroid treatment, prednisone/
methylprednisolone at a dosage of \1 mg/kg/day or
oral beclomethasone dipropionate (BDP) (low dose),
and prednisone/methylprednisolone at a dosage of $1
mg/kg/day (high dose). Oral BDP is used to treat
gastrointestinal GVHD and has an active metabolite
that reachespulmonarycirculationandmaypreventnon-
infectious pulmonary complications after HCT [22-24].
Dexamethasone doses were converted to a prednisone
equivalent dose and patients were assigned accordingly.
Corticosteroid dose considered was the highest dose
taken during the 2 weeks preceding influenza diagnosis.
For the analysis of viral shedding duration, we only
analyzed data obtained from nonmolecular methods in
patients who had 2 or more upper respiratory tract
specimens sampled. The last day of excretion was con-
sidered to be the day in the middle of the period be-
tween the last positive and the first negative test, and
shedding duration was calculated only if there were
nomore than 14 days between the last positive and first
negative test.
Statistical Analysis
Patient characteristics were summarized, and trans-
plant and other demographic factors were compared us-
ing chi-square test or Fisher’s exact test for categoric
variables (as appropriate); linear regression (ANOVA),
Wilcoxon rank sumtest, orKruskal-Wallis testwereuti-
lized for comparisons of continuous variables. The fol-
lowing 6 endpoints were evaluated: (1) LRD, (2)
hypoxemia, (3) mechanical ventilation, (4) time to
influenza-associated mortality, (5) time to mortality of
all causes, and (6) prolonged shedding (viral excretion
.14 days). Univariable and multivariable logistic
Biol Blood Marrow Transplant 17:979-986, 2011 981Influenza After HCTregression models were used to estimate odds ratios
(ORs) and 95% confidence intervals (CIs) for LRD,
hypoxemia, mechanical ventilation, and prolonged
shedding. The probability of survival was estimated by
the Kaplan-Meier method, and univariable hazards for
mortalitywere comparedusing log-rank tests.Multivar-
iable Cox proportional hazards models were used to
evaluate adjusted hazard ratios (HR) for mortality.
Covariates evaluated as candidates for inclusion in mul-
tivariable models were corticosteroid treatment, URI
antiviral therapy, lymphocyte count, infection year,
gender, underlying disease, disease risk, donor match,
hematopoietic cell source, and acuteGVHD(aGVHD).
Variables with P value\.30 in the univariable models
were retained for the multivariable models. Once
included in a full multivariable model, factors were
excluded in step-down and step-up fashion and kept in
if their P values were\.10 or if their inclusion modified
the effect of corticosteroid treatment by .10%. Corti-
costeroid treatment,URI antiviral therapy, and lympho-
cyte count were forced into themultivariablemodels for
all endpoint analyses. All reported P values are 2-sided
and considered significant at a\ .05.RESULTS
Clinical Manifestations
During the study period, 143 HCT recipients who
developed seasonal influenza infectionhaddata available
for analysis.Patients’ characteristics are listed inTable 1,
and clinical outcomes are presented in Tables 2 and 3.
Overall, 32 (22%) patients developed a LRD, 33
(23%) were hypoxemic, and 13 (9%) required
mechanical ventilation. Death within 42 days occurred
in 17 (12%) patients, and influenza caused or
contributed to death in 12 (8%) patients. Among the
32 patients who developed a LRD, 12 (38%) required
mechanical ventilation and 12 (38%) died as
a consequence of influenza infection. Median time of
progression to LRD in the patients who initially
presented with a URI was 13 days (range: 4-32 days).
Twenty-five (78%) LRD cases were diagnosed with
lower respiratory tract specimens. Among the 13 me-
chanically ventilated patients, 9 (69%) died in the 42
days following diagnosis because of influenza infection,
and the median mechanical ventilation duration was 7
days (range: 1-22 days). Eighty-seven (61%) patients
had2ormoreupper respiratory tract specimens sampled
that permitted viral clearance analysis.Median shedding
duration was 7 days (interquartile range [IQR], 5-12
days) andviral excretion lasting longer than14days (pro-
longed shedding) occurred in 29% of patients.
Impact of Corticosteroid Treatment
Some differences were observed between the 3 dif-
ferent corticosteroid treatment groups (Table 1). Spe-cifically, patients treated with corticosteroids acquired
their influenza infection later after transplantation and
had less advanced underlying diseases. As expected,
there were more recipients of allogeneic transplanta-
tion and subjects with aGVHD in the corticosteroid-
treated groups.We first compared the 3 corticosteroid
treatment groups in univariable analyses, and no sig-
nificant difference was documented for LRD, hypox-
emia, mechanical ventilation, or death (data not
shown). The Kaplan-Meier probability of survival
showed no difference between the 3 different cortico-
steroid treatment groups (Figure 1). In univariable
analyses, treatment with corticosteroids was not associ-
ated with prolonged shedding (data not shown). Treat-
mentwith corticosteroids hadno impact on coinfection
rate. The incidence of infections with copathogens was
21%, 19%, and 19%, for patients who respectively re-
ceived no steroids, low dose or high dose of steroids.
Multivariable analyses were carried out for each
clinical outcome studied (Table 4), and no statistically
significant difference was seen between the 3 different
corticosteroid groups for LRD, hypoxemia, mechani-
cal ventilation, and death. Multivariable analyses
showed a borderline association between high doses
of corticosteroids and prolonged shedding, whereas
treatment with low doses was not associated with pro-
longed shedding. Both univariable and multivariable
analyses for each clinical outcome were also performed
in the subgroup of patients who had only a URI at pre-
sentation. These analyses led to similar results (data
not shown) with the exception of delayed viral clear-
ance, which did not reach statistical significance for
the higher steroid dosages in the multivariable analysis
(OR, 2.5; 95% CI, 0.7-8.3, P 5 .14).Impact of Antiviral Therapy and Risk Factors
for Severe Influenza Infection
Precise antiviral therapy history was available for
142 (99%) influenza episodes and 58 (41%) patients
were treated duringURI phase. Sixteen (28%) patients
received a M2-inhibitor, 40 (69%) were treated with
a neuraminidase inhibitor, and 2 (3%) were given
drugs from 2 or more classes. The median time for ini-
tiation of therapy was 1 day (IQR, 1-2 days), and 45
(32%) patients had their therapy initiated within 2
days following diagnosis. Eighty-four (59%) patients
were not treated for URI, but 21 (25%) of them re-
ceived antiviral therapy after LRD diagnosis. Among
the 21 patients who had antiviral therapy initiated after
LRD diagnosis, 7 (33%) died due to influenza infec-
tion. Characteristics of patients who received URI an-
tiviral therapy were compared to patients who did not,
and treated patients had less profound lymphopenia
(13% versus 37%, P\ .01) and were more likely to
be diagnosed during the 2000 to 2009 period (74%
versus 36%, P\ .01).
Table 1. Characteristics of Hematopoietic Cell Transplant Recipients with Influenza Infection
Corticosteroid Treatment
Characteristic
None
n 5 63
Low Dose*
n 5 43†
High Dose*
n 5 37
All Patients
N 5 143
Year
1989-1999 33 (52) 17 (40) 19 (51) 69 (48)
2000-2009 30 (48) 26 (61) 18 (49) 74 (52)
Median age (IQR), years 42 (32-51) 42 (28-53) 40 (32-54) 42 (31-53)
Male sex 36 (57) 29 (67) 18 (49) 83 (58)
Median time post-transplant (IQR), days 43 (10-110) 111 (71-541) 80 (60-116) 73 (40-197)
Underlying disease
Acute leukemia 20 (32) 19 (44) 13 (35) 52 (36)
Chronic leukemia 14 (22) 9 (21) 8 (22) 31 (22)
Lymphoma 8 (13) 4 (9) 3 (8) 15 (11)
Multiple myeloma 8 (13) 3 (7) 4 (11) 15 (11)
Myelodysplasia 3 (5) 4 (9) 8 (22) 15 (11)
Others 10 (16) 4 (9) 1 (3) 15 (11)
Disease risk
Nonadvanced 28 (44) 30 (70) 20 (54) 78 (55)
Advanced 35 (56) 13 (30) 17 (46) 65 (46)
Donor match
Autologus 21 (33) 4 (9) 1 (3) 26 (18)
Allogeneic, matched related 19 (30) 17 (40) 19 (51) 55 (39)
Allogeneic, mismatched related or unrelated 23 (37) 22 (51) 17 (46) 62 (43)
Cell source
Bone marrow or UBC 31 (49) 18 (42) 16 (43) 65 (46)
PBSC 32 (51) 25 (58) 21 (57) 78 (55)
Acute GVHD
No 51 (81) 15 (35) 6 (16) 72 (50)
Yes 12 (19) 28 (65) 31 (84) 71 (50)
Lymphocytes count
<100 cells/mL 16 (26) 10 (24) 12 (32) 38 (27)
100-300 cells/mL 14 (23) 13 (31) 14 (38) 41 (29)
>300 cells/mL 31 (51) 19 (45) 11 (30) 61 (44)
Influenza type
A 43 (68) 27 (63) 33 (89) 103 (72)
B 20 (32) 16 (37) 4 (11) 40 (28)
Antiviral therapy for URI
Yes, #48 hours‡ 19 (30) 14 (33) 12 (32) 45 (32)
Yes, >48 hours‡ 7 (11) 3 (7) 3 (8) 13 (9)
No 37 (68) 25 (60) 22 (60) 84 (59)
GVHD indicates graft-versus-host disease; IQR, interquartile range; PBSC, peripheral blood stem cell; UBC, umbilical cord blood; URI, upper respiratory
tract infection.
Note: data are number (%) of patients, unless otherwise indicated.
*Low dose: <1 mg/kg or oral beclomethasone diproprionate. High dose: $1 mg/kg.
†Six patients received oral beclomethasone diproprionate (BDP) only, and 37 patients received systemic corticosteroid at dosage <1 mg/kg with or
without oral BDP.
‡Time from viral diagnosis to initiation of antiviral therapy.
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any time to treat an URI was associated with fewer oc-
currences of LRD and hypoxemia (Table 3) and better
survival at 42 days (Figure 2). Inmultivariable analyses,
antiviral therapy for URI was still associated with a sta-
tistically significant decreased risk of LRD and hypox-
emia and showed a trend toward reduced mortality
(Table 4). We also analyzed the impact of timing of
initiation of antiviral therapy for URI in univariable
analyses. Compared to the incidence observed in pa-
tients who were not treated for URI, the incidence of
LRD was lower in both subgroups of patients who
initiated their antiviral therapy #48 hours (4% versus
29%, P\ .01) or .48 hours following URI diagnosis
(8% versus 29%, P 5 .05).
Multivariable analyses showed that profound lym-
phopenia (\100 cells/mL) was a significant risk factorfor LRD, need for mechanical ventilation, and death
in HCT recipients infected with influenza (Table 4).
The incidence of LRD was higher during the 2000
to 2009 period compared to the 1989 to 1999 period
in univariable analysis, although the difference was
not statistically significant (all LRD: 27% versus
17%, P 5 .22; proven LRD [diagnosed with lower
tract specimens] 23% versus 12%, P 5 .08). There
was no difference in need for mechanical ventilation
(7% versus 12%, P 5 0.39) or influenza-associated
mortality (8% versus 9%, P 5 1.0), respectively, be-
tween the 2000 to 2009 and 1998 to 1999 periods.
However, in the subgroup of patients with LRD, the
need for mechanical ventilation was lower during the
2000 to 2009 period (35% versus 67%, P 5 .03).
Influenza-associated mortality was also lower in
patients with LRD during the 2000 to 2009 period,
Table 2. Clinical Outcomes of Hematopoietic Cell Transplant Recipients with Influenza Infection According to Corticosteroid
Treatment
Corticosteroid Treatment
Clinical Outcome
None
n 5 63
Low Dose*
n 5 43†
High Dose*
n 5 37
All Patients
N 5 143
Site of influenza infection
URI only 47 (75) 36 (84) 28 (76) 111 (78)
URI followed by LRD 4 (6) 2 (5) 2 (5) 8 (6)
LRD at diagnosis 12 (19) 5 (12) 7 (19) 24 (17)
Hypoxemia 16 (25) 10 (23) 7 (19) 33 (23)
Mechanical ventilation 9 (14) 3 (7) 1 (3) 13 (9)
Influenza-associated deaths‡ 6 (10) 2 (5) 4 (11) 12 (8)
Deaths‡ 7 (11) 5 (12) 5 (14) 17 (12)
Prolonged shedding¶ 11 (25) 3 (16) 11 (46) 25 (29)
LRD indicates lower respiratory tract disease; URI, upper respiratory tract infection.
Note: data are number (%) of patients.
*Low dose: <1 mg/kg or oral beclomethasone diproprionate. High dose: $1 mg/kg.
†Six patients received oral beclomethasone diproprionate (BDP) only, and 37 patients received systemic corticosteroid at dosage <1 mg/kg with or
without oral BDP.
‡During the first 42 days following influenza diagnosis.
¶Defined as viral excretion >14 days. Only 87 patients with available data for this analysis.
Biol Blood Marrow Transplant 17:979-986, 2011 983Influenza After HCTalthough the difference was not statistically significant
(30% versus 50%, P 5 .29). In multivariable analyses,
the 2000 to 2009 period was associated with an in-
creased risk of LRD OR 5.7 (95% CI, 1.7-2.0), P\
.01), but was not associated with any other adverse
clinical outcome (data not shown).DISCUSSION
This study evaluated the largest number of HCT
patients infected with seasonal influenza to date, and
provides new insights into the impact of antivirals and
corticosteroid therapies in this high-risk population.
We confirmed the severity of influenza disease in this
population as approximately 1 in 4 patients developed
LRD and became hypoxemic, and 1 in 10 patients re-
quired mechanical ventilation and died of respiratory
causes related to influenza virus infection [1-4]. This
study also suggests that corticosteroids, mainly given
for the management of GVHD, have no adverse
outcome when given at modest doses. In addition, weTable 3. Univariable Analysis of Impact of URI Antiviral Therapy
Infection (N 5 142)
URI Antiviral Th
Clinical Outcome
No (n 5 84)
n (%)
Lower respiratory tract diseases 29 (35)
Hypoxemia 26 (31)
Mechanical ventilation 10 (12)
Influenza-associated deaths† 10 (12)
Deaths† 14 (17)
Prolonged shedding‡ 16 (34)
CI indicates confidence interval; HR, hazard ratio, OR, odds ratio; URI, upper
*Odds ratios are shown as lower respiratory tract disease, hypoxemia, mechan
time to death and influenza-associated death.
†During the first 42 days following influenza diagnosis.
‡Defined as viral excretion >14 days. Only 87 patients with available data forfound beneficial effects of antiviral therapy initiated
at any time during the URI phase.
The role of corticosteroids in the management of
influenza is controversial. Our study suggests that corti-
costeroid treatment was not associated with adverse
clinical outcomes in HCT recipients infected with in-
fluenza virus. Interestingly, treatment with low doses
of corticosteroids showed a trend toward a lower risk
of LRD (Table 4). It should be pointed out that cortico-
steroid treatment was not initiated with the intent-
to-treat influenza infection, but rather, it was part of
the patients’ treatment regimen for GVHD in most
cases. Therefore, steroid recipients tended to be further
out from HCT. Nevertheless, several conclusions can
be drawn from these data. First, our results suggest
that corticosteroids at modest doses can be safely con-
tinued in HCT patients during an influenza episode.
This is an important concept because clinicians some-
times reduce corticosteroid doses in the context of an
infection because of concern of adverse effects on viral
replication. However, whether corticosteroids shouldin Hematopoietic Cell Transplant Recipients with Influenza
erapy
Yes (n 5 58)
n (%)
OR or HR*
(95% CI) P
3 (4) 0.1 (0.0-0.4) <.01
6 (10) 0.3 (0.1-0.8) .01
3 (4) 0.5 (0.1-1.8) .25
2 (2) 0.3 (0.0-1.2) .09
3 (4) 0.3 (0.1-1.0) .05
9 (23) 0.6 (0.2-1.5) .27
respiratory tract infection.
ical ventilation, and prolonged shedding, and hazard ratios are shown for
this analysis.
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Figure 1. Kaplan-Meier analysis. Comparison of overall survival to 42
days after diagnosis of influenza infection in hematopoietic cell trans-
plant recipients who were receiving either no corticosteroids, low-
dose corticosteroids (\1 mg/kg or oral beclomethasone dipropionate),
or high-dose corticosteroids ($1 mg/kg) at the time of infection. Log-
rank test P value 5 .92.
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not treated with corticosteroids at the time of infection
cannot be conclusively determined. Our data contrast
with data on paramyxoviruses (eg, parainfluenzavirus
3), for which corticosteroid treatment has been associ-
ated with an increased risk of progression to LRD in
oncology patients [13,14]. Consequently, this suggests
that immunomodulation by corticosteroids may have
differing effects depending upon the specific
respiratory virus. Because our study only included
seasonal influenza, our conclusions cannot be
extrapolated to infection with novel strains of
influenza. Data on the impact of corticosteroid
treatment on swine-derived 2009 A/H1N1 or avian A/
H5N1 influenza infections are contradictory. A recent
report showed that corticosteroid treatment was well
tolerated in patients with acute respiratory distressTable 4. Multivariable Analyses of Impact of Corticosteroid Treat
Outcomes
Lower Respiratory
Tract Disease Hypoxemia
Mechanical
Ventilation
Variable OR (95% CI) P OR (95% CI) P OR (95% CI)
Corticosteroid treatment
None Reference Reference Reference
Low dose‡ 0.3 (0.1-1.1) .10 1.3 (0.4-4.0) .50 0.4 (0.1-2.4)
High dose‡ 0.8 (0.2-2.4) .60 0.9 (0.3-3.3) .69 0.2 (0.0-1.9)
URI antiviral therapy
No Reference Reference Reference
Yes 0.04 (0-0.2) <.01 0.3 (0.1-0.9) .03 0.7 (0.2-3.3)
Lymphocyte count (cells/mL)
>300 Reference Reference Reference
100-300 2.0 (0.5-7.5) .93 0.9 (0.3-2.9) .33 0.7 (0.1-7.3)
<100 4.3 (1.3-15) .04 2.6 (0.9-7.0) .05 6.4 (1.5-28)
CI indicates confidence interval; HR, adjusted hazard ratio; OR, adjusted odd
Notes: Corticosteroid treatment, URI antiviral therapy, and lymphocyte coun
cluded infection year and cell source for lower respiratory tract disease analysis
ventilation analysis, disease risk for time to influenza-associated death and tim
*During the first 42 days following influenza diagnosis.
†Defined as viral excretion >14 days.
‡Low dose: <1 mg/kg or oral beclomethasone diproprionate. High dose: $1following A/H1N1 influenza infection [10], whereas
another study found an association of steroid use with
LRD; however, the latter study did not analyze the
effect of steroid dose and had a small sample size [25].
Two studies including a limited number of A/H5N1
avian influenza-infected patients reported no associa-
tion between corticosteroid therapy and mortality; but
in a larger study, corticosteroids use was associated
with an increased risk of death [26-28].
Our study looked at the impact of different cortico-
steroid dosing regimens on viral clearance. Although
earlier studies showed that corticosteroids prolong in-
fluenza shedding [4,12], these studies did not analyze
the amount of steroid exposure. We found a trend
toward prolonged shedding with high doses, but there
was no effect on shedding duration with low doses of
corticosteroids or oral BDP. This observation has
possible implications on influenza transmission, as it
suggests that modest doses of corticosteroids may not
alter the risk of transmission because of prolonged
shedding in these high-risk hosts. The prolonged shed-
ding associated with high corticosteroid dosing also rai-
ses the questionwhether patients receiving highdoses of
steroids could possibly benefit from longer antiviral
treatment duration. Whether longer viral clearance
time induced by high doses of corticosteroid and pro-
longed treatment is associatedwith an increase in antivi-
ral resistanceneeds tobedetermined. A limitationof our
results is that we only analyzed data obtained from non-
molecular diagnostic test. However, improved sensitiv-
ity of molecular methods is mainly evident for 2009 A/
H1N1, which was not included in the present study
[29-31]. Also, any possible diagnostic bias would likely
not have been affected by the steroid dosing regimens.
Our study is the first report showing that antiviral
therapy initiated during URI decrease the risk of LRDment, Antiviral Therapy, and Lymphocyte Count on Clinical
Time to Influenza-
Associated Death* Time to Death*
Prolonged
Shedding†
P HR (95% CI) P HR (95% CI) P OR (95% CI) P
Reference Reference Reference
.90 0.5 (0.1-2.5) .40 1.1 (0.4-3.6) .85 0.5 (0.1-2.5) .11
.27 0.9 (0.3-3.3) .89 1.1 (0.3-3.5) .87 3.3 (1.0-11) .05
Reference Reference Reference
.68 0.3 (0.1-1.4) .11 0.3 (0.1-1.1) .07 0.9 (0.3-3.0) .84
Reference Reference Reference
.24 2.0 (0.3-15) .48 1.9 (0.5-7.6) .64 0.4 (0.1-2.0) .14
<.01 7.5 (1.5-37) .01 3.8 (1.1-13) .03 1.5 (0.4-5.2) .18
s ratio; URI, upper respiratory tract infection.
t were included as variables in all analyses. Multivariable models also in-
, cell source and aGVHD for hypoxemia analysis, aGVHD for mechanical
e to death analyses, and cell source for prolonged shedding analysis.
mg/kg.
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Figure 2. Kaplan-Meier analysis. Comparison of overall survival to 42
days after diagnosis of influenza infection for hematopoietic cell trans-
plant recipients who received antiviral therapy for upper respiratory
tract infection versus those who did not received therapy. Log-rank
test P value 5 .03.
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only other retrospective study with multivariable
analyses showed a borderline statistical association be-
tween LRD and lack of URI treatment with antivirals
[2].We also evaluated the impact of timing of initiation
of antiviral therapy in univariable analysis. Our results
suggest that even delayed antiviral therapy for URI
could possibly reduce the risk of LRD, although the ef-
fect is probably diminished. Larger studies are needed
to examine this issue. Nevertheless, our data support
the recommendation that antiviral therapy should to
be started as soon as possible after URI diagnosis.
The increased risk of LRD associated with the
2000 to 2009 period remains unexplained. The higher
rate did not appear to be related to a change in URI
diagnostic because our policy to obtain a nasal wash
when patients develop URI symptoms was similar
during the 2 periods; if anything, there was a higher
awareness and likelihood of testing in the more recent
years. The finding was also not due to a higher rate of
probable LRD cases because the difference remained
significant when we excluded patients who did not un-
dergo bronchoscopy. One possible explanation is the
increased outpatient management during the later pe-
riod. Because systemic influenza symptoms are often
masked in immunocompromised patients and URI
symptoms may be minimal [32], patients could have
developed LRD by the time they seek medical assis-
tance. Also, the observation that the use of
mechanical ventilation and influenza-associated mor-
tality were lower in patients with LRD during the
2000 to 2009 period suggests that more milder cases
of LRD were diagnosed during the later period. The
more frequent use of computerized tomography of
the chest during the 2000 to 2009 period compared
to the earlier period could possibly explain the in-
creased in diagnostic yield of milder LRD cases.
Our study has strengths and limitations. The retro-
spective nature of our analysismay have introducedunin-tendedbiases.Differences for certain variables among the
3 corticosteroid groups were present because of the fact
that corticosteroids were mainly given to treat aGVHD.
However, the multivariable models included several
important variables and permitted us to address, at least
partially, these biases. The lower number of patients
with profound lymphopenia in the patients who received
early antiviral therapy could have had an impact on uni-
variable analyses, but the inclusion of this variable in
the multivariable analyses should have addressed this
concern. Also, the fact that the study period extended
over 2 decades may have introduced a bias with regard
to influenza diagnostic or supportive care. However,
the inclusionof the periodduringwhich influenzawas di-
agnosed in the multivariable analyses showed no change
in the steroidor antiviral effect overtime.Wechosenot to
include swine-derived A/H1N1 cases because of the rel-
atively small number of cases and endpoints during the
study period and the possibility that the steroid effect
may be strain specific [26-28]. Finally, we did not
evaluate all patients with continuing viral shedding for
resistance in a systematic manner. Nevertheless, this
study includes the largest cohort of immunosuppressed
patients with seasonal influenza disease and permitted
multivariable statistical modeling to minimize the
impact of possible confounders.
In conclusion, our data suggest that even high
doses of corticosteroids given mainly for the manage-
ment of GVHD have no deleterious clinical effect in
HCT patients infected with seasonal influenza. In-
deed, the use of low to moderate doses showed a trend
toward beneficial effect for LRD. The only adverse
outcome we detected was a borderline significant delay
of viral clearance where light doses of steroids were
used. Thus, steroid treatment may have a paradoxical
effect, in that it potentially improves clinical outcomes
likely through suppression of inflammatory cytokines,
whereas, at the same time, it leads to prolonged viral
shedding. The data suggest that most of a possible
benefit would be obtained when low to modest doses
of corticosteroids or compounds such as BDP are
used.We believe our data provide the rationale to con-
duct prospective randomized clinical trials to test the
hypothesis whether adjunctive short-term, low-dose
use of corticosteroids is beneficial in the management
of influenza disease in immunocompromised patients.
Adjunctive use of corticosteroids is beneficial in other
infectious diseases with strong inflammatory responses
such as Pneumocystis jirovecii pneumonia, herpes zoster,
and bacterial meningitis [33-35]. Finally, our study
found that antiviral therapy for URI is associated
with a risk reduction of LRD and hypoxemia.ACKNOWLEDGMENTS
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